Evidence map›Paper›PMID 24816648›Full record

ArticlePloS one2014

Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay.

Elena S Gavrilova, Sergey A Bobrovnik, Gordon Sherriff, Andrey A Myslivets, Sergey A Tarasov, Oleg I Epstein

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elena S GavrilovaOOO "NPF "MATERIA MEDICA HOLDING", Moscow, Russian Federation.
Sergey A BobrovnikDepartment of Molecular Immunology, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, Ukraine.
Gordon SherriffAb Biotechnology Limited, Penicuik, United Kingdom.
Andrey A MyslivetsOOO "NPF "MATERIA MEDICA HOLDING", Moscow, Russian Federation.
Sergey A TarasovOOO "NPF "MATERIA MEDICA HOLDING", Moscow, Russian Federation.
Oleg I EpsteinOOO "NPF "MATERIA MEDICA HOLDING", Moscow, Russian Federation.
National Academy of Sciences of Ukraine · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selection of a suitable assay to measure the activity of drug agents based on release-active forms of anti-interferon-gamma antibodies (RA forms of Abs) is an important step forward in the investigation of such agents. In this study, the enzyme-linked immunosorbent assay was utilized to examine the effect of RA forms of Abs specific for human interferon gamma on the interaction between monoclonal anti-interferon gamma antibodies and recombinant human interferon gamma. The experimental data and the results obtained by using relevant mathematical analysis showed that such RA forms of Abs are able to modulate the monoclonal antibody interaction with both soluble and immobilized (to the assay plate well) interferon gamma. These data demonstrated the importance of using relatively low concentrations of both soluble and plate-immobilized interferon gamma to detect the effects of RA forms of Abs to interferon gamma on the binding of monoclonal antibodies to interferon gamma. It has been suggested that the observed influence of RA forms of Abs on 'antibody-antigen' interaction could be used to detect and analyze the activity of drugs containing RA forms of Abs.

Indexed as

Antibodies, MonoclonalEnzyme-Linked Immunosorbent AssayHumansImmobilized ProteinsInterferon-gammaSolubilityAntibodies, MonoclonalIFNG protein, humanImmobilized ProteinsInterferon-gamma

Identifiers

PMID24816648
PMCPMC4016219
OpenAlexW2048477819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.